Combo First to Show Overall Survival Benefit in Certain Colorectal Cancers: STELLAR-303 Data at ESMO 2025

2 months ago 93

Zanzalintinib plus atezolizumab (Tecentriq) is the first immunotherapy-based combination to show an overall survival benefit in certain metastatic colorectal cancers.

1. Homepage
2. Lung Cancer
3. Combo First to Show Overall Survival Benefit in Certain Colorectal Cancers: STELLAR-303 Data at ESMO 2025